Our Leadership Team
Our team has a track record of working together and between them have launched multiple successful commercial enterprises encompassing drugs, digital health, diagnostics and devices. The team have full experience of technology development through to market access, reimbursement and uptake.
Dr Andy Richards CBE
Dr Andy Richards has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK), Sensiia Ltd, and Cambridge University Hospitals NHS Foundation Trust. As well as being an advisor to Cambridge Innovation Capital, he also advises the UCL Technology Fund. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.
Dr Richards is a graduate of the University of Cambridge with a PhD in Chemistry.
Dr Hakim Yadi OBE
Chief Executive Officer & Co-Founder
Hakim is a Co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.
As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health - and therefore wealth and well-being -outcomes.
Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.
Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration.
Hakim started his career at PA Consulting, where he co-managed the company's translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).
He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.
Dr Paul Goldsmith
Chief Innovation Officer, President & Co-Founder
Dr Paul Goldsmith was awarded a triple 1st from Cambridge and a clinical scholarship from Oxford. Following general medical training, he sub-specialised in neurology, before completing a PhD in a development biology lab, taking a systems biology approach to understanding human disease. He was the principal founder of DanioLabs Ltd in 2002, which utilised disease modeling for systematic drug repurposing, established discovery programmes in several areas and generated a product pipeline, the most advanced of which now has positive Phase 2 data.
He was then part of the team that reinvigorated Psychology Online Ltd, a digital health company, with a new business plan, management team and financing. He co-founded Rubrum Ltd in 2012 to provide semi-automated healthcare provision in insomnia, pain and COPD to the NHS and other markets through a proprietary online platform and was NED there until 2014. He was also co-founder of Vastrata Ltd, which focused on reprofiling and repurposing, with a virtual business model.
He also has extensive NHS operational and strategic experience, including being NHS England Northern Strategic Clinical Networks (SCN) neuro lead (to May 16), and sitting on a NHS England Urgent and Emergency Care Vanguard and the north Clinical Senate.
He has in excess of 50 peer reviewed publications and patent applications.
Dr David Cox
Chief Digital Officer & Co-Founder
Dr David Cox has built a career operating on the boundaries between healthcare, technology and business. He graduated from Cambridge and then Imperial Medical School, and practiced medicine in a busy central London Accident & Emergency department for several years before pursuing a management career, gaining experience first at McKinsey & Co. After working in both strategic and operational management roles back in the NHS, he focused on the growing promise of digital health, starting his own health app company, and then moving on to help grow other startups in senior management positions.
David has been published in The Lancet, the American Journal of Physiology and the Health Service Journal and is a mentor on the NHS Clinical Entrepreneur Training programme.
Dr Felicity Sartain
Chief Operations Officer & Co-Founder
Felicity is a Chemist with over 10 years of managerial, commercial and research experience in the life sciences, and med tech. She has successfully delivered a range of complex projects and programmes in both the private and public sectors. She founded Profiscio, a consultancy business to support the translation and manage the development of scientific innovation.
Prior to this she co-founded NanoScientium, specifically focussed on supporting nanomedicine enterprises, and was the Programme Director at Bio Nano Consulting. There, she managed and delivered multimillion-pound nanotechnology projects, developed market and business opportunities and secured global contracts. Additionally, Felicity led the Healthcare and Life Sciences Theme for the Nanotechnology Knowledge Transfer Network (KTN), supporting the exploitation and commercialisation of micro and nanotechnologies across the UK.
She was a co-inventor of the original technologies at Smart Holograms, a Cambridge University spin-out that designed and developed novel biosensors. Prior to this worked in Research and Development at GSK where she developed microfluidic drug discovery platforms.
Felicity holds an MChem in Chemistry with Life Sciences and Pharmaceuticals from the University of York, and a PhD from the University of Cambridge. She is an advisor to the European Healthtech Translation Advisory Board (HealthtechTAB), a Member of Royal Society of Chemistry and a STEMNet Ambassador.